Since 2014, Sen-Jam has been on a mission to revolutionize pain management - driven to usher in a new dawn for humanity around full strength living

Sen-Jam has been working hard amassing 25 both domestic and international patents and patents pending

  • October

    COVID-19 Phase II Clinical Trial Secured

    Press Release: Sen-Jam Pharmaceutical secures Phase II Clinical Trial for COVID therapy SEN-JAM PR Oct 12 2021 Pill for COVID treatment Trials

  • September

    Intellectual Property Update

    In support of Sen-Jam's mission to improve societal well-being, our Patent Application No. 11,129,803B2 for Methods and Compositions to Inhibit Tolerance to Opioids was granted by the United States Patent and Trademark Office on September 28th.

  • September

    Novel Solutions for Addressing Traditional Treatment Deficits

    Press Release: Sen-Jam Pharmaceuticals addresses deficits with traditional treatments for COVID-19 as well as OPIOID WITHDRAWAL SEN-JAM PR Sept 28 2021 COVID Treatment

  • August

    Press Release

    Sen-Jam Pharmaceutical Enters Phase I Clinical Study on Alcohol Hangover Treatment

  • August

    Press Release

    Sen-Jam Pharmaceutical Partners With Duke-NUS Medical School for a Phase 2 Trial for a New COVID 19 Treatment

  • July

    Mid-Year Stakeholder Update

    Sen-Jam Pharmaceutical Stakeholder Mid-Year Update

  • May

    Intellectual Property Update

    Australian Patent Granted AU2016235484B2 for Methods and Compositions to Inhibit Symptoms Associated with Veisalgia (SJP-001) (Alcohol Hangover Prevention)

  • May

    Intellectual Patent Update

    Japan Patent Granted JP6851365B2 for Methods and Compositions to Inhibit Symptoms Associated with Veisalgia (SJP-001) (Alcohol Hangover Prevention)

  • April

    Intellectual Patent Update

    South Africa Patent Granted 201706794B for Methods and Compositions to Inhibit Symptoms Associated with Veisalgia (SJP-001) (Alcohol Hangover Prevention)

  • March

    COVID-19 Research Paper Published

    In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2

  • February

    Licensing Update

    Sen-Jam has executed a licensing term sheet with Haltzak Biopharma for SJP-002C (COVID-19 Treatment) for Colombia with expansion rights to Central and South America.

  • February

    Intellectual Patent Update

    Received Notice of Patent Allowance from the Japanese Intellectual Patent Office for SJP-001 (Alcohol Hangover Prevention)

    Received Notice of Acceptance from the Australian Patent Office for SJP-001 (Alcohol Hangover Prevention)

  • February

    Opioid Withdrawal Research Papers Published

    Functional observation after morphine withdrawal: effects of SJP-005

    A Comparison of the Antinociceptive Properties of SJP-005 and Morphine in Rats

    2021

  • December

    Intellectual Property Update

    US Patent Award No. 10,874,653 for Methods and Compositions to Inhibit Adverse Effects of Vaccinations (SJP-003)

  • October

    Licensing Update

    Sen-Jam has executed a licensing term sheet with Haltzak Biopharma for SJP-001 (Hangover Prevention) for Colombia with expansion rights to Central and South America.

  • September

    Intellectual Property Update

    US Patent Award No. 10,765,630 for Methods and Compositions to Treat Enteropathic Arthritis (SJP-004)

  • July

    Sen-Jam Pharmaceutical Secures Funding for COVID-19 Treatment

  • June

    Completed Mentorship program for 2 Northeastern Capstone groups

    Sen-Jam wins Life Science Nation Digital RESI Innovation Challenge

    Interview published Treatment Before Vaccine: How Two Medical Scientist Hope to Buy Time for COVID-19 Patients

    Presented COVID-19 Treatment at BIO, BIONJ, and RESI

  • June

    Intellectual Property Update

    US Patent Award No. 10,675,261 for Methods and Compositions to Inhibit Dependence of Opioids (SJP-006)

  • May

    Selected as Finalist for Life Science Nation Digital RESI Innovation Challenge

    Selected as Featured Company for Life Science Nation Digital RESI COVID-19 Solution Presentation

    Selected to Present COVID-19 Solution at Biotechnology Innovation Organization (BIO) Digital Conference

    Entered Collaborative Partnership Agreement with Assistance Publique - Hopitaux De Paris to Study Treatments for COVID-19

    Featured in COVID-19: Treatments before Vaccines Webinar with AdvancedDx Biological Laboratories

  • April

    In-Vitro Study underway testing SJP-002 against the COVID-19 virus

    Listed on RedCrow’s Equity CrowdFunding site

    Sen-Jam featured in StartUp Healths Insights

  • March

    Alcohol Hangover Paper Published featuring SJP-001

  • March

    Off-Label use of our Opioid Withdrawal Product used in tapering Suboxone

  • January

    Sen-Jam participates in StartUp Health Festival during JP Morgan Health Conference

    2020

  • Fall

    Sen-Jam attends RESI conference and pushes greater insight on Opioid Use Disorder

  • November

    Presented at Life Science Summit, NYC

  • Fall

    Patent issued for SJP-001

  • September

    Led panel discussion for Opioid Crisis Working Group

  • August

    Highlighted in Real Leaders Magazine for work related to opioid withdrawal

  • July

    Op Ed published in StartUp Health Magazine

  • June

    Partnered with Stony Brook University - Center for Biotechnology

  • Spring

    Conducted additional pre-clinical studies for opioid withdrawal (SJP-005)

  • January

    Sen-Jam participates in StartUp Health Festival, the premier forum of Health Transformers during JP Morgan Health Conference

    2019

  • Fall

    Sen-Jam attends RESI conference and pushes greater insight on Opioid Use Disorder

  • June

    Sen-Jam attends Research Society on Alcoholism Conference

  • May

    Sen-Jam attends BioTech event at Cold Spring Harbor Labs

  • Spring

    Spring pre-clinical studies for opioid withdrawal (SJP-005)

  • March

    Sen-Jam files patent for treatment of enteropathic arthritis (SJP-004)

  • January

    Sen-Jam attends JP Morgan Health Conference

    2018

  • November

    Sen-Jam Wins RESI Innovation Challenge

  • October

    Sen-Jam first Corporate Retreat

  • September

    Sen-Jam files patents to inhibit symptoms associated with opioid withdrawal (SJP-005), opioid dependence (SJP-006), and opioid tolerance (SJP-007)

  • August

    Sen-Jam files patent to inhibit adverse effects associated with vaccinations (SJP-003)

  • August

    Sen-Jam Pharmaceutical LLC is formed

  • July

    Sen-Jam attends Research Society on Alcoholism Conference

  • June

    Investigational New Drug (IND) application opened with the FDA to begin Phase I Clinical Trial

  • June

    Sen-Jam files patent to inhibit symptoms associated with Viral Respiratory Infections (SJP-002)

  • April

    Sen-Jam presents in Amsterdam at 9th annual Alcohol Hangover Research Group Conference

    2017

  • October

    Sen-Jam completes Pre-Investigational new drug meeting with FDA

  • August

    Trademarks filed & Scientific Advisory Board established

  • June

    Sen-Jam presents findings to Alcohol Hangover Research Group at National Institute on Alcohol Abuse and Alcoholism Conference

  • March

    Conducted IRB Study for Prevention of Alcohol Hangover (SJP-001)

    2016

  • March

    Provisional Patents Filed

    2015

  • Fall

    Volunteer Study Begins—SJP-001

  • Spring

    Jackie Iversen has Eureka moment

    2014